Abstract: A stereoscopic vision system uses at least two cameras having different parameters to image a scene and create stereoscopic views. The different parameters of the two cameras can be intrinsic or extrinsic, including, for example, the distortion profile of the lens in the cameras, the field of view of the lens, the orientation of the cameras, the positions of the cameras, the color spectrum of the cameras, the frame rate of the cameras, the exposure time of the cameras, the gain of the cameras, the aperture size of the lenses, or the like. An image processing apparatus is then used to process the images from the at least two different cameras to provide optimal stereoscopic vision to a display.

Abstract: Embodiments described herein are directed to optical systems creating an optical image on an image sensor, the optical image having at least one foveated region of interest created using at least one localized magnification optical feature on an optical surface. The optical system can be useful to increase the number of infrared pixels that are used to image a specific target which is only in a part of the object scene, while still being able to image the whole scene in the RGB part of the spectrum. In a preferred embodiment, the optical system is used in an automotive scenario to image with higher resolution the driver in order to more efficiently run face tracking and recognition algorithms.

Abstract: A method and apparatus for analyzing side-channel security vulnerabilities in a digital device. A first time sequence of measurements of side-channel related phenomena of the digital device, such as power draw or electromagnetic emissions is obtained. A second time sequence of debug outputs of the digital device, such as program counter contents or other device processor or register states, is obtained. The first time sequence and the second time sequence are obtained based on a common time reference, and thus correlated in time. A controller can provide a common timing signal to measurement equipment obtaining the first time sequence and to a debug tool obtaining the second time sequence, and the common time reference can be correspond to the common timing signal.

Abstract: Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by a large proportion of AML cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as AML is also described.

Abstract: A device comprises at least one pair of excitation electrodes forming a capacitor; a floorplan (e.g., a ground plane); and an electronic circuit. The device comprises at least one control electrode arranged at a distance from the capacitor. A switching circuit, of the device, comprises a switch having an open state and a closed state. The switching circuit is designed to apply, to the control electrode, an electric potential common to the floorplan when the switch is in the closed state. The switching circuit is also designed to leave a floating electrical potential for the control electrode when the switch is in the open state. The electronic circuit is designed to measure the mutual capacitance between the pair of excitation electrodes when the switch is in the open state and when it is in the closed state.

Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILs) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.

Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.

Abstract: Acute lymphoblastic leukemia (ALL) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) specifically expressed by ALL cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of leukemia such as ALL is also described.

Abstract: Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is unknown. Novel tumor-specific antigens (TSAs) shared by a large proportion of ovarian tumors are described herein. Most of the TSAs (>80%) described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of ovarian cancer is also described.

Abstract: A device, for capacitive measurement of a height of a fluid in a tank, comprises at least one pair of capacitors extending in a longitudinal direction. A first capacitor forms first geometric patterns defining a first line capacitance. A second capacitor is opposite the first capacitor and forms second geometric patterns defining a second line capacitance. The first and second geometric patterns are arranged so that the first and second line capacitances, integrated in the longitudinal direction, have a sum that depends on the position of the fluid in the longitudinal direction. The first and second line capacitances, integrated in the longitudinal direction, have a difference that is a constant for reference positions of the fluid in the longitudinal direction.

Abstract: A method and apparatus for analyzing side-channel security vulnerabilities in a digital device. A first time sequence of measurements of side-channel related phenomena of the digital device, such as power draw or electromagnetic emissions is obtained. A second time sequence of debug outputs of the digital device, such as program counter contents or other device processor or register states, is obtained. The first time sequence and the second time sequence are obtained based on a common time reference, and thus correlated in time. A controller can provide a common timing signal to measurement equipment obtaining the first time sequence and to a debug tool obtaining the second time sequence, and the common time reference can be correspond to the common timing signal.

Abstract: T cells, notably CD8 T cells, are known to be essential players in tumor eradication as the presence of tumor-infiltrating lymphocytes (TILS) in several cancers positively correlates with a good prognosis. To eliminate tumor cells, CD8 T cells recognize tumor antigens, which are MHC I-associated peptides present at the surface of tumor cells, with no or very low expression on normal cells. Described herein a proteogenomic approach using RNA-sequencing data from cancer and normal-matched mTEChi samples in order to identify non-tolerogenic tumor-specific antigens derived from (i) coding and non-coding regions of the genome, (ii) non-synonymous single-base mutations or short insertion/deletions and more complex rearrangements as well as (iii) endogenous retroelements, which works regardless of the sample's mutational load or complexity.

Abstract: A device comprises at least one pair of excitation electrodes forming a capacitor; a floorplan (e.g., a ground plane); and an electronic circuit. The device comprises at least one control electrode arranged at a distance from the capacitor. A switching circuit, of the device, comprises a switch having an open state and a closed state. The switching circuit is designed to apply, to the control electrode, an electric potential common to the floorplan when the switch is in the closed state. The switching circuit is also designed to leave a floating electrical potential for the control electrode when the switch is in the open state. The electronic circuit is designed to measure the mutual capacitance between the pair of excitation electrodes when the switch is in the open state and when it is in the closed state.

Abstract: Minor histocompatibility antigens (MiHAs) binding to certain human leukocyte antigen (HLA) alleles are described. These MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these MiHAs are also described. The present application also discloses the use of these MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.

Abstract: A system and method for communicating data between a first software and a second software located on first and second devices, respectively, has a hardware driver and memory associated with each device. Each communication of data from the first software to the second software allocates memory to manage data to be communicated from the first software to the second software, provides memory allocation information to the hardware driver associated with the first software, and transmits the data from the first hardware driver to the second hardware driver for delivery to the second software via the memory associated with the second software.

Abstract: Novel minor histocompatibility antigens (MiHAs) are described. These novel MiHAs were selected based on two features: (i) they are encoded by loci with a minor allele frequency (MAF) of at least 0.05; and (ii) they have adequate tissue distribution. Compositions, nucleic acids and cells related to these novel MiHAs are also described. The present application also discloses the use of these novel MiHAs, and related compositions, nucleic acids and cells, in applications related to cancer immunotherapy, for example for the treatment of hematologic cancers such as leukemia.

Abstract: A secure generic encryption system for nonsecure datapaths comprises a format-specific adaptation layer/data path for receiving and processing nonsecure content data; an authentication engine located within a security perimeter and coupled to an external communication interface for authentication and supplying the format-specific adaptation layer/data path, located outside the security perimeter, with an output signal indicating whether authentication is successful; and a generic encryption module located within the security perimeter and coupled (1) to the authentication engine for receiving from the authentication engine initialization vectors, encryption keys, and the output signal indicating whether authentication is successful, and (2) to the format-specific adaptation layer/data path for (a) receiving a read signal from the format-specific adaptation layer/data path, and (b) providing the format-specific adaptation layer/data path with a data-available signal to indicate whether data is available to be